Kyowa's BioWa subsidiary grants ImmunoCellular rights to its Potelligent technology to develop ImmunoCellular's antibodies for cancer and an option to license any resulting Abs

Kyowa Hakko Kirin Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

ImmunoCellular Therapeutics Ltd.

U.S. / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced